Marlowe Share Discussion Threads

[dunns_river_falls] 15/6/2023 19:34

Interesting given the mcap of MRL is £570m

[prokartace] 08/6/2023 09:57

Technicals suggest the current rally will peak around 600p A break above that will allow share price to move to 700p

[1nf3rn0] 08/6/2023 07:23

Rising nicely into the full year results announcement (expected end of this month)

[saucepan] 31/3/2023 18:09

The market seems to be reacting well to the trading update and the chart is looking good: arguably an uptrend is now in place; with 800p as significant resistance to overcome at some point. The potential gains on offer, to only get to that stage, are not to be sniffed at.

[dr biotech] 29/3/2023 16:22

I'll try and listen to the webinar on friday as the share price seemed to pick up during/after it. I have decent hopes for this lot - can't see any press coverage about it though. As with many others it needs some deleverage on the back of rising rates.


...

[prokartace] 29/3/2023 09:41

Double bottom formed or wishful thinking?

[prokartace] 28/3/2023 07:52

All depends on the level of trust you have in the company's promise that it will become increasingly cash rich and therefore how long it will take to reduce the current level of debt

[dr biotech] 28/3/2023 07:29

Results seem pretty much in line. Revenue and adjusted EBITDA slightly ahead, but debt is also higher. All caused by the one takeover that was not announced. I guess the focus on the debt is the cause of the drop


From the former Cenkos note (I expect a new one shortly)

Actual (predicted)

Revenue 475 (470)
Adj EBITDA 87 (82)
Debt 170 (163.8)

Still looks like decent value to me, but they need to deleverage and I'd like to know whats "adjusted"

[dr biotech] 07/3/2023 07:59

Yeah, would be very odd to schedule a capital markets day if the news was going to be bad, although they have one every year (a good thing imo). They mentioned the current trading last year -though the announcement was closer to the period end


Capital Markets Day 2022

At the event, senior executives and operational management will provide an update on:

-- The significant progress made in building the Marlowe compliance platform and delivering against the Group's medium-term financial and strategic targets set out at our last Capital Markets Day (17 February 2021); and

-- A deep-dive into the Group's Governance, Risk and Compliance division focusing on our software and consultancy offering.

Group trading

The Group continues to make strong financial and strategic progress, and trading for the year ending 31 March 2022 is expected to be in line with current market expectations.

The integration programmes of all recent completed acquisitions are proceeding as planned with synergies being delivered in line with expectations.

[saucepan] 07/3/2023 07:46

Trading update confirmed for 28 March, and the gist already outlined in today's RNS, i.e.:

-- The Group's continued strong progress towards and confidence in achieving March 2024 financial targets of GBP500m of run-rate revenue and GBP100m of run-rate EBITDA

-- How the Group drives improved organic growth and margin expansion through the integration and restructuring of acquisitions

-- Marlowe's underlying highly cash generative profile and the Group's forward expectations for significant free-cash flow generation

-- The resilience of the Marlowe model and the growth of the business and its markets.

Sounds good.

[mcmather] 28/2/2023 12:21

2p spread instead of the 'usual' 10p; hmmm.

(now 1p @ 12.30hrs)

[dr biotech] 23/2/2023 16:53

Well you can always use your retrospective broker to sell at higher price as you did above.

[1nf3rn0] 23/2/2023 11:53

Now trading at just 5x run rate EBITDA and less than 1x RR Revenue.Let's hope they are making progress on improving the cash flow metrics, which is what the market is now judging them on.There was a trading update last year on 21st March, so I'd expect some news by end of next month.

[dr biotech] 18/1/2023 08:18

Had a cenkos note this morning about their software offering, looks like a decent high margin business. Was an update from their well attended capital markets day.

[wad collector] 11/1/2023 18:39

I keep a lot of shares for the same reason:-)

[dr biotech] 11/1/2023 16:25

I have c4000 here - its one of my largest positions. Bought 2k at 455 before xmas - timing could have been better. Only have one other larger individual holding, plus a few funds and trusts that are bigger. But I doubt its enough to shift the needle. I did once have to sell a share in two lots as it was bigger than the NMS but that was still a modest amount

FWIW my lowest value share is OXB which I've held for 20 years and is worth about £250. Cost me about £2000. I keep them as a reminder that patience in often not rewarded and not to get emotionally attached to a company.

[prokartace] 11/1/2023 16:00

Dr. Bio, if you are as small as you make it sound you should only have 10 shares and the rest in a trust!

Would have been a nice one to buy as a xmas present!

[dr biotech] 30/12/2022 10:37

Must be some bigger retail punters than me (unsurprisingly).

I currently have 37 individual stocks and I’m looking to cull this to 25 over the next few months. This is one I’m more likely to keep as I think it’ll do ok in the medium term.